Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor

Supporting evidence

• Evaluation report

• Final appraisal determination committee papers (PDF 4.63 MB)

  Published:

  27 January 2021